Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares are now listed on the Luxembourg Stock Exchange under the ticker symbols PHECA and PHECR.
Funding to Fuel Global Expansion and R&D
The proceeds from this offering will be instrumental in supporting PharmaEssentia’s strategic growth plans, with a particular focus on expanding the indications for the company’s flagship product, Besremi (ropeginterferon alfa-2b-nhft), in global markets. Besremi, discovered in-house, is approved in the EU, US, and Japan for the treatment of the rare disease polycythemia vera (PV). The company is also actively engaged in the ongoing development of Besremi for the treatment of solid tumors, indicating a robust pipeline and commitment to advancing novel therapies.-Fineline Info & Tech
